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Summary objective To compare the cost-effectiveness of malaria treatment based on presumptive diagnosis with
that of malaria treatment based on rapid diagnostic tests (RDTs).
methods We calculated direct costs (based on experience from Ethiopia and southern Sudan) and
effectiveness (in terms of reduced over-treatment) of a free, decentralised treatment programme using
artesunate plus amodiaquine (AS + AQ) or artemether-lumefantrine (ART-LUM) in a Plasmodium
falciparum epidemic. Our main cost-effectiveness measure was the incremental cost per false positive
treatment averted by RDTs.
results As malaria prevalence increases, the difference in cost between presumptive and RDT-based
treatment rises. The threshold prevalence above which the RDT-based strategy becomes more expensive
is 21% in the AS + AQ scenario and 55% in the ART-LUM scenario, but these thresholds increase to 58
and 70%, respectively, if the ﬁnancing body tolerates an incremental cost of 1 € per false positive
averted. However, even at a high (90%) prevalence of malaria consistent with an epidemic peak, an
RDT-based strategy would only cost moderately more than the presumptive strategy: +29.9% in the
AS + AQ scenario and +19.4% in the ART-LUM scenario. The treatment comparison is insensitive to
the age and pregnancy distribution of febrile cases, but is strongly affected by variation in non-bio-
medical costs. If their unit price were halved, RDTs would be more cost-effective at a malaria prevalence
up to 45% in case of AS + AQ treatment and at a prevalence up to 68% in case of ART-LUM treatment.
conclusion In most epidemic prevalence scenarios, RDTs would considerably reduce over-treatment
for only a moderate increase in costs over presumptive diagnosis. A substantial decrease in RDT unit
price would greatly increase their cost-effectiveness, and should thus be advocated. A tolerated incre-
mental cost of 1 € is probably justiﬁed given overall public health and ﬁnancial beneﬁts. The RDTs
should be considered for malaria epidemics if logistics and human resources allow.
keywords Plasmodium falciparum, malaria, epidemic, rapid diagnostic test, presumptive treatment,
cost-effectiveness
Introduction
Malaria epidemics are increasingly frequent, and, at least
in sub-Saharan Africa, tend to occur in populations already
made vulnerable by poverty, malnutrition and/or armed
conﬂict (Kiszewski & Teklehaimanot 2004). Past research
on malaria epidemics has largely focussed on forecasting
and early detection. By contrast, there is very little evidence
on appropriate operational responses once epidemics do
occur (Worrall et al. 2004). The World Health
Organization (WHO) currently recommends prioritising
case management, and providing free, highly efﬁcacious
artemisinin-based combination therapy (ACT) from the
start at all levels of care (WHO 2004).
As regards diagnosis, WHO guidelines contemplate
presumptive antimalarial treatment of all febrile patients.
Under this strategy, diagnostic sensitivity is maximised
(i.e. almost all cases are detected), and the case manage-
ment algorithm is greatly simpliﬁed, facilitating the rapid
decentralisation of care to the most peripheral levels, where
community health workers (CHWs) may be entirely in
charge of diagnosis and prescription (WHO 2004).
Presumptive treatment, however, has serious disadvanta-
ges because of its very poor speciﬁcity (many fever cases will
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pathology). This can, depending on the prevalence of
malaria among febrile patients, lead to signiﬁcant misdiag-
nosis andover-treatment.Over-treatment, in turn,increases
drug costs; creates favourable conditions for the emergence
of resistant strains; and leaves non-malaria patients without
the drugs they need, and with a false perception of cure,
which could delay their recourse to alternative therapies in
case symptoms persist or worsen (Amexo et al. 2004).
Highly sensitive and speciﬁc rapid Plasmodium falcipa-
rum rapid diagnostic tests (RDTs) are available, and, given
their ease of use and interpretation, could potentially be
deployed at the peripheral level in epidemics, given a
minimal degree of training, logistics and quality assurance
(WHO 2003). From the ﬁnancial standpoint, the public
health improvement inherent in RDT deployment might
result either in additional expenditures (due to the cost of
testing) or signiﬁcant savings (due to reduced use of
expensive ACT drugs). Here, we present a cost-effective-
ness analysis of RDT-supported vs. presumptive diagnosis
in malaria epidemics where ACT is used.
This work is based on the experience of the medical non-
governmental organisationMe ´decins SansFrontie `res(MSF)
during two recent malaria emergency interventions in
southern Sudan, where 76 400 patients were treated over
6 months (Checchi 2004), and in Ethiopia, where 21 340
patients were treated over 4 months (Priotto 2003) (corres-
ponding reports are freely available from the authors). In
both sites, both RDTs and presumptive diagnosis were used
at varying times in the epidemiological curve, and in
different facilities, including peripheral health units.
Methods
Context
We considered a hypothetical P. falciparum epidemic
context in a sub-Saharan Africa country, where poor access
to formal health care structures leads to the establishment
of temporary malaria treatment centres, operated at the
peripheral level by relatively unskilled CHWs, and offering
free treatment for uncomplicated malaria only. Treatment
consists of ACT, quinine for pregnant women for whom
ACT is contra-indicated and paracetamol.
Within this context, we compared two diagnostic and
treatment strategies: (i) a presumptive strategy in which all
patients with fever or a history of fever receive antimalarial,
and (ii) an RDT-based strategy in which all patients with
feverorahistoryoffeveraretestedbytheParacheck-Pf test
(Orchid Biomedical Systems, India), and receive antimalar-
ial only if they are test-positive. Paracheck-Pf  is an RDT
detectingtheP.falciparumHistidineRichProtein2antigen.
We did separate analyses for two ACT scenarios:
artesunate plus amodiaquine (AS + AQ) and the
more expensive artemether-lumefantrine or Coartem
TM
(ART-LUM). We chose these combinations because they
are currently prioritised by the WHO for use throughout
Africa. Both are available in blister form, but currently
only ART-LUM is a ﬁxed combination (i.e. both drugs are
contained within one tablet).
Parameter inputs
Population proﬁle. The posology of ACT is dependent on
the patient’s weight (ART-LUM) or age (AS + AQ): ACT
costs would thus be greatly affected by the age distribution
of fever and/or malaria infection. In addition, ACT is
contra-indicated in the ﬁrst trimester (AS + AQ) or
throughout pregnancy (ART-LUM), and quinine is
generally prescribed instead. For these reasons, we needed
to make assumptions about the age and pregnancy status
proﬁle of our model population of febrile patients.
Speciﬁcally, we had to determine (i) the proportion of
patients that would fall within the dosage categories
speciﬁed by current AS + AQ (Sanoﬁ-Aventis) and ART-
LUM (Novartis) blister packs (Table 1), and (ii) the
proportion of patients who would be treated with quinine
instead because of pregnancy.
In classical epidemics, host susceptibility to malaria is
high irrespective of age and pregnancy status, and asymp-
tomatic infections are rare (Kiszewski & Teklehaimanot
2004): based on these considerations, we assumed for our
main analysis that (i) the age and pregnancy status
distribution of febrile patients (see Population proﬁle,
Table 1) would resemble that in the general sub-Saharan
African population (US Census Bureau 2004), (ii) the
prevalence of malaria infection would be uniform across
age groups and unaffected by pregnancy status and
(iii) fever accompanied by a positive RDT result would
equate to true symptomatic malaria.
Furthermore, we assumed that CHWs would be unable
to distinguish new from repeat visits, and would thus treat
each patient as a novel case (i.e. prescribe only ﬁrst-line
regimens).
Cost inputs. We calculated costs in Euros (as of August
2004, 1 Euro ¼ 1.219 USD) per 10 000 febrile patients
consulting in a period of 1 month (Table 1). This unit rate
seemed appropriate, as it allowed us to factor in time-
dependent costs (such as salaries), and since caseload is
actually far higher in most serious epidemics (WHO 1998).
Items and their values were extracted from MSF Sudan and
Ethiopia operational accounts (reporting actual
expenditures), or supplied by MSF’s procurement agency
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1. Population proﬁle Proportion (uncertainty) Notes on uncertainty
Malaria prevalence (0–100%)
Age/pregnancy distribution: AS + AQ scenario
<7 years 21% (up to 39%) Relative risk of
fever (RR) up to 3.0
7–13 years 19% (up to 23%) RR up to 2.0
>13 years 59% (as low as 36%) Reference group
Pregnant (ﬁrst trimester) 1% (up to 2%) RR up to 3.0
Weight/pregnancy distribution: ART-LUM scenario
<15 kg (<4 years) 12% (up to 22%) RR up to 3.0
15–24 kg (4–7 years) 12% (up to 19%) RR up to 2.5
25–34 kg (8–11 years) 11% (up to 14%) RR up to 2.0
‡35 kg (‡12 years) 62% (as low as 39%) Reference group
Pregnant (all trimesters) 3% (up to 6%) RR up to 3.0
2. Cost inputs Quantity
Unit cost
(uncertainty) Notes
2. a Biomedical costs Per test or treatment Costs include 3% freight
RDTs 1 Paracheck kit 0.53
1 pair of gloves (as low as 0)
Drugs: AS + AQ scenario
<7 years 1 AS + 1 AQ · 3 days 0.43 Quantities refer to daily tablets of
AS, AQ, QN (quinine) or
paracetamol (PC) · number of
days (d).
0.9 PC · 2 days
7–13 years 2 AS + 2 AQ · 3 days 0.81
3P C· 2 days
>13 years 4 AS + 4 AQ · 3 days 1.61 Within the <7 years group there are
two dosage categories, but only one
pack (caregivers of small children
must split tablets)
6P C· 2 days
Pregnant (ﬁrst trimester) 6 QN · 7 days 1.51
6P C· 2 days
Drugs: ART-LUM scenario
<15 kg (<4 years) 2 ART-LUM · 3 days 0.89 Quantities refer to daily co-formulated
tablets of ART-LUM, plus quinine
and paracetamol as above.
0.6 PC · 2 days
15–24 kg (4–7 years) 4 ART-LUM · 3 days 1.45
1.2 PC · 2 days
25–34 kg (8–11 years) 6 ART-LUM · 3 days 1.89
3P C· 2 days
‡35 kg (>11 years) 8 ART-LUM · 3 days 2.38
6P C· 2 days
Pregnant (all trimesters) 6 QN · 7 days 1.51
6P C· 2 days
2. b Other costs Per 10 000 patients
per month
CHWs Presumptive: 32 136
RDT-based: 48 (0.5 to 2 times)
Supervisors Presumptive: 2 875
RDT-based: 2 (0.5 to 2 times)
Drivers Presumptive: 4 171
RDT-based: 5 (0.5 to 2 times)
Vehicle rental and fuel Presumptive: 4 1555
RDT-based: 5 (0.5 to 2 times)
3. Effectiveness inputs Percent Notes
Sensitivity
Presumptive strategy 100% Estimates of RDT sensitivity and speciﬁcity
are the average of manufacturer speciﬁcations
and the following studies: (Proux et al. 2001;
Guthmann et al. 2002; Huong et al. 2002; Singh et al. 2002)
RDT-based strategy 95%
Speciﬁcity
Presumptive strategy 0%
RDT-based strategy 94%
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of what an international non-governmental relief
organisation would incur. For simplicity’s sake, items that
accounted for negligible budget contributions (less than
1%) were excluded. We did not include costs of training on
RDT use.
Based on programmatic data from southern Sudan and
Ethiopia, we calculated that each treatment centre would
consist of a team of two (presumptive strategy) or three
(RDT-based strategy) CHWs working 4 days a week, 6 h
a day, with a turnover of 10 min per consultation (i.e.
625 consultations per month per team, or 32 CHWs per
10 000 patients per month under the presumptive strat-
egy and 48 under the RDT-based strategy). The pro-
gramme would be supervised by two coordinators, and
supported by vehicles and drivers at a ratio of one per
10 CHWs.
Effectiveness inputs. We looked at effectiveness from the
standpoint of diagnosis of true symptomatic malaria
among febrile patients. We assumed that the Paracheck
RDT would be highly sensitive and speciﬁc, while
presumptive diagnosis would have had perfect sensitivity
and zero speciﬁcity (Table 1). Our main effectiveness
measure was the number of false positives averted.
Data analysis
Main cost-effectiveness analysis. We used TreeAge Pro
Suite 5.1 software (Tree Age Inc., Williamstown, MA,
USA) to construct and analyse our model. As the main
public health advantage of introducing RDTs would be to
minimise over-treatment, we adopted as our primary cost-
effectiveness outcome the incremental cost per false
positive treatment averted. This indicator represents the
added cost to the programme if one wished to prevent one
unit case of over-treatment by using RDTs instead of
presumptive diagnosis. This is an incremental cost-
effectiveness ratio, and takes the following form:
incremental cost/false positive averted
¼
cost of RDT-based strategy-cost of presumptive stragey
false positive averted by RDT-based strategy
;
where the number of false positives averted is given by the
total number of non-malaria cases times the RDT’s
speciﬁcity. The incremental cost tends to increase if the
RDT-based strategy costs signiﬁcantly more than pre-
sumptive diagnosis, and decrease if RDTs prevent a great
number of false positives. A negative incremental cost
implies that the RDT-based strategy is ‘dominant’, namely
costs less and is more effective.
As secondary cost-effectiveness outcome, we calculated
the cost per true positive malaria case treated, expressed as:
cost/true malaria
case treated
¼
cost of strategy
number of true positives detected
;
where the number of true positives detected is given by
the number of true malaria cases times the strategy’s
sensitivity.
We also calculated overall costs of the two strategies per
unit of 10 000 febrile patients per month (these however
do not include costs of drugs to treat non-malaria fever
cases, since they are unrelated to our effectiveness
measure).
Sensitivity analyses. Along with comparing the two
strategies at different levels of malaria ‘prevalence’ (deﬁned
here as the proportion of true malaria cases among all fever
cases), we did sensitivity analyses to observe the effect on
cost-effectiveness outcomes of uncertainty in certain
parameters (Table 1). These parameters were (i) the age
and pregnancy status distribution of patients: contrary to
our initial assumption, we hypothesised that younger
individuals and pregnant women would experience higher
rates of fever due to malaria or other illnesses, or present
more often to health centres and would thus be
overrepresented among the population of febrile patients
(Theander 1998; Boisier et al. 2002); (ii) the price of the
RDT test, assuming a future price reduction; (iii) the total
non-biomedical costs (i.e. excluding drugs and RDTs),
assuming up to twofold inter-country differences due to
variation in salaries, transportation and other logistics
costs (MSF Logistique, personal communication). We did
not conduct a sensitivity analysis of the price of ACT, as
AS + AQ and ART-LUM seemed to provide realistic lower
and upper-end estimates of foreseeable future prices.
Tolerance in incremental costs. Policy decisions might be
based not merely on whether a strategy is likely to be cost-
effective, but rather on whether an overall ﬁnancial and/or
public health beneﬁt of this strategy could be achieved if
the decision maker were prepared to tolerate an additional
expenditure. For this reason, we also compared the two
strategies assuming that ﬁnancing bodies would be willing
to tolerate an incremental cost of up to 1 € or 2 € per false
positive averted.
Results
Main cost-effectiveness analysis. As malaria prevalence
increases, the difference in cost (per 10 000 fever
consultations per month) between the presumptive and
Tropical Medicine and International Health volume 11 no 4 pp 398–408 april 2006
E. Rolland et al. Cost-effectiveness of rapid diagnostic tests in malaria epidemics
ª 2006 Blackwell Publishing Ltd 401RDT-based strategies becomes more substantial: Table 2
illustrates this for low (25%), medium (50%) or high
(75%) values of malaria prevalence. The threshold
prevalence above which the RDT-based strategy becomes
more expensive is 21% in the AS + AQ scenario, and
55% in the ART-LUM scenario (data not shown).
However, cost differences are relatively modest
(Table 2), and even at a very high prevalence (90%),
only +30% (€ 32 634 vs. € 25 108) for AS + AQ, and
+19% (€ 39 525 vs. € 33 112) for ART-LUM.
The incremental cost per false positive case averted
increases exponentially with prevalence, and varies con-
siderably according to the ACT used. As above, when
prevalence exceeds 21% (AS + AQ) or 55% (ART-LUM)
(Figure 1a,b), preventing a case of over-treatment
through RDTs entails a positive incremental cost. Con-
versely, below these prevalences the RDT-based strategy
results in lower costs, i.e. is dominant. However, if the
ﬁnancing body is willing to tolerate an incremental cost
of up to 1 € per false positive averted, these prevalence
thresholds become 58% (AS + AQ) and 70% (ART-
LUM), meaning the RDT-based strategy is favoured in a
wider range of possible prevalence scenarios. At the
above prevalence thresholds, a tolerance of 1 € equates
to a difference in total costs of less than +16% (€ 29 190
vs. € 25 108) for AS + AQ, and +9% (€ 35 948 vs.
€ 33 112) for ART-LUM. The thresholds rise further
(though less considerably) if tolerance is up to 2 €.
Sensitivity analyses. If the unit cost of a Paracheck kit is cut
by half (to € 0.27), the RDT-based strategy is dominant up
to prevalence thresholds of 45% for AS + AQ and 68% for
ART-LUM (Figure 2a,b). If, in addition, incremental cost
tolerance up to 1 € per false positive averted is introduced,
these thresholds increase substantially (up to 70%) for
AS + AQ, but modestly (up to 78%) for ART-LUM.
Doubling tolerance to 2 € does not greatly affect
thresholds.
Cost-effectiveness is less sensitive to variation in the
age and pregnancy distribution of the febrile patient
population (Figure 3a,b). However, in the AS + AQ
scenario the presumptive strategy becomes dominant at
even zero malaria prevalence when the relative propor-
tion of young children and pregnant women is greatest
(Table 1).
Inter-country variation in non-biomedical costs strongly
affects the strategy comparison (Figure 4a,b): in the
AS + AQ scenario, presumptive treatment is the dominant
choice at any malaria prevalence if only these costs were
1.6 times higher than the amount we estimated.
Discussion
In this cost-effectiveness analysis considering a malaria
epidemic situation in which ACT is used at the peripheral
level of care, we could not demonstrate a clear-cut cost-
effectiveness superiority of either presumptive diagnosis or
an RDT-based strategy, mainly due to the dynamic nature
of prevalence during an epidemic. Nevertheless, given the
current price of most rapid tests and ACT, the RDT-based
strategy would avoid much over-treatment, and greatly
improve management of non-malaria fever cases, with only
Table 2 Cost-effectiveness outcomes at three different levels of malaria prevalence
Prevalence ¼ 25% Prevalence ¼ 50% Prevalence ¼ 75%
Presumptive
strategy
RDT-based
strategy
Presumptive
strategy
RDT-based
strategy
Presumptive
strategy
RDT-based
strategy
Fever cases 10 000 10 000 10 000 10 000 10 000 10 000
True malaria cases 2500 2500 5000 5000 7500 7500
True cases detected 2500 2375 5000 4750 7500 7125
False negatives 0 125 0 250 0 375
False positives 7500 450 5000 300 2500 150
False positives averted 0 7050 0 4700 0 2350
AS + AQ scenario
Total cost (€) 25 108 25 638 25 108 28 329 25 108 31 019
Cost difference (%) – +2% – +13% – +24%
Cost/true malaria case detected (€) 10.0 10.8 5.0 6.0 3.3 4.4
Incremental cost/false positive averted (€) – +0.1 – +0.6 – +2.5
ART-LUM scenario
Total cost (€) 33 112 27 900 33 112 32 371 33 112 36 842
Cost difference (%) – )16% – )2% – +11%
Cost/true malaria case detected (€) 13.2 11.7 6.6 6.8 4.4 5.2
Incremental cost/false positive averted (€)– )0.7 – )0.2 – +1.6
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ﬁnancing bodies were willing to tolerate an added cost of
up to 1 € per false positive averted (namely a total cost
increase of less than 20%), RDTs would be favoured in a
majority of scenarios. Even higher tolerance, however,
might not bring about substantial added beneﬁts. Unit test
price is a major determinant of the cost-effectiveness of
RDTs.
The evolution of prevalence in the course of a malaria
epidemic may largely determine which strategy would be
more cost-effective if used consistently. If the epidemic
peak were sustained over most of the intervention period,
presumptive diagnosis would be more cost-effective over-
all, whereas a shorter peak followed by progressively
declining prevalence would favour RDTs. Timing of RDT
introduction with respect to the epidemic peak would also
be important. Here we presented a comparison for only
1 month of intervention. If better data on the typical
evolution of malaria epidemics were collected, the analysis
could be extended to the entire epidemic period. It should
be noted here that malaria prevalence in the general
population might not accurately reﬂect prevalence among
fever cases presenting for treatment. The latter indicator
would be affected not only by malaria transmission, but
AS + AQ scenario
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Figure 1 a,b Incremental cost per false-positive treatment averted,
as a function of malaria prevalence (AS + AQ scenario and
ART-LUM scenario). Vertical bars indicate prevalence thresholds
(%) below which the RDT-based strategy is cost-effective,
according to whether the decision maker tolerates an incremental
cost per false positive averted of 0 €,u pt o1€,o ru pt o2€.
ART-LUM scenario
AS + AQ scenario (a)
(b)
Figure 2 a,b Sensitivity analysis of RDT price: incremental cost
per false-positive treatment averted, as a simultaneous function of
unit test price (Y-axis) and malaria prevalence (X-axis) (AS + AQ
scenario and ART-LUM scenario). Diagonal lines represent dif-
ferent levels of incremental cost tolerance. In a scenario of zero
cost tolerance, the RDT-based strategy is dominant at any com-
bination of RDT price and malaria prevalence that falls in the grey
area. If tolerance is increased, the decision favours RDTs at even
higher prices or malaria prevalences (all combinations to the left of
the respective tolerance line). *indicates value in main analysis.
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seeking patterns. It should therefore be measured sepa-
rately for cost-effectiveness purposes. In Ethiopia (2003),
southern Sudan (2003) and Burundi (2000), 64, 60 and
80% of fever cases were RDT-positive at epidemic peak
(MSF unpublished data). Rapid surveys of fever patients
could inform the strategy decision during future epidemics:
when proportionate malaria morbidity surpasses the pre-
dicted cost-effectiveness threshold, RDT use could be
suspended.
As expected, RDTs are much more cost-effective if the
more expensive ART-LUM regimen is used, rather than
AS + AQ. Cost-effectiveness is not strongly affected by
variation in the age and pregnancy proﬁle of the patient
population; however, a scenario in which children or
pregnant women are overrepresented among fever cases
(probably typical of some emergency programmes targeting
these groups especially, or of semi-immune settings where
non-pregnant adults are less susceptible to symptomatic
malaria) does favour presumptive treatment, since drug
costs decrease. Conversely, the cost-effectiveness of RDTs is
greatly increased as their price declines. The strategy
comparisonisalsoverysensitivetointer-countryvariationin
non-biomedical programmecosts.Wecalculatedthese costs
based on MSF programmatic experience: however, costs
might well be higher or lower depending on the set up of
treatment programmes implemented in other contexts.
It should be noted that our comparison of total expen-
ditures under the two strategies does not take into account
costs of drugs used to treat non-malaria fevers, since we
only considered malaria-speciﬁc treatment centres and
looked at an effectiveness outcome strictly related to
malaria diagnosis.
In epidemic settings where access to health care may be
poor, the public health advantages of more speciﬁc
diagnosis should be weighed carefully against the dangers
of reduced sensitivity. However, febrile illnesses incorrectly
diagnosed and treated only as malaria in a presumptive
AS + AQ scenario
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Figure 3 a,b Sensitivity analysis of age and
pregnancy status distribution: incremental
cost per false-positive treatment averted, as
a simultaneous function of variation in age
and pregnancy distribution of febrile
patients (Y-axis) and malaria prevalence
(X-axis) (AS + AQ scenario and ART-LUM
scenario). Diagonal lines represent different
levels of incremental cost tolerance.
Towards the top of the graph, children and
pregnant women are over-represented
among fever cases, whereas towards the
bottom the age and pregnancy distribution
of fever cases resembles that in the general
population (i.e. our initial assumption).
*indicates value in main analysis.
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Their case-fatality ratio (CFR) would depend on the
proportionate aetiology of such fevers in any setting or
season.
In short, there is a balance between the harms of malaria
cases missed due to imperfect RDT sensitivity and the
beneﬁts of better management of non-malaria fevers. This
harm-beneﬁt balance would favour presumptive treatment
if the malaria treatment programme were implemented
vertically in a setting with little other access to health care,
and RDT use if alternative treatment for non-malaria
febrile illnesses were available. We illustrate this roughly in
Table 3 for children under 5, where we calculate the net
beneﬁt (as deaths averted and hospital cost savings per
false positive diagnosis averted) of RDTs in two scenarios
of low (25%) and high (75%) access to outpatient and
inpatient health care, and hypothesizing a 50% malaria
prevalence. Here, we assume conservatively that, out of all
non-malaria fever cases, only 50% would be due to
potentially fatal acute respiratory infections (ARI), while
the rest would be self-limiting (in reality other potentially
fatal aetiologies, such as febrile diarrhoeas, could occur).
The RDTs would probably save lives due to better ARI
management, and result in a hospital cost saving of 0.6 €
per false positive averted in a scenario of good health
access (Table 3). This saving is close to our proposed
tolerance level of 1 €, demonstrating that such an
additional expenditure may be ultimately justiﬁable on
cost-beneﬁt, if not strictly cost-effectiveness, grounds. In
the long-term, prevention of drug resistance represents an
additional ﬁnancial and public health beneﬁt further
tipping the balance towards RDTs. However, the future
impact of drug pressure on parasite sensitivity to ACT
combinations (especially ART-LUM), for which potential
resistance mechanisms are only now being elucidated, is
unknown: the corresponding beneﬁt per unnecessary
treatment averted by RDTs is thus hard to predict.
Much would also depend on the quality of RDT
handling and use. Based on published evidence, we
assumed near-ideal RDT effectiveness. Post-implementa-
tion studies of RDT use, however, would be helpful to
obtain more likely estimates of these tests’ accuracy in
routine African conditions (Premji et al. 1994). It is also
likely that better diagnosis would considerably reduce
indirect costs to both consumer and provider because of
shorter illness, decreased re-visits, and less recourse to
treatments for severe conditions. These costs were not
included in our analysis, but have been estimated to
account for as much as 80% of total (Breman et al. 2004).
Our ﬁndings are probably not applicable to stable
malaria settings, where the assumption ‘fever plus test-
positivity ¼ malaria’ would not be appropriate due to
frequent asymptomatic infections, especially among adults.
In such settings, a better comparison would be between
presumptive treatment and an RDT-supported clinical
algorithm aiming to maximise both positive and negative
predictive values. Furthermore, microscopy should be
included among the diagnosis options in stable contexts.
The RDT use in malaria epidemics may be constrained
by several factors, such as insufﬁcient human resources and
training capacity, and inadequate procurement, transport
and stocking procedures and logistics (Bualombai et al.
2003). Nevertheless, we feel that, as in other malaria-
related issues today, the right health economics question to
ask is not only whether a proposed intervention is likely to
ART-LUM scenario
AS + AQ scenario (a)
(b)
Figure 4 a,b Sensitivity analysis of inter-country variation in non-
biomedical costs: incremental cost per false-positive treatment
averted, as a simultaneous function of variation in non-biomedical
costs (Y-axis) and malaria prevalence (X-axis) (AS + AQ scenario
and ART-LUM scenario). Diagonal lines represent different levels
of incremental cost tolerance. *indicates value in main analysis.
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if ﬁnancing bodies are willing to tolerate higher spending,
as seems unavoidable to give Roll Back Malaria a chance of
success. Our analysis contributes to answering this ques-
tion by indicating broadly the ﬁnancial implications
decision makers should expect if the choice were taken to
deploy RDTs in malaria epidemics. Interestingly, decreased
test prices would make the RDT strategy much more cost-
effective: along with securing lower ACT prices, interna-
tional campaigns should therefore also aim for more
affordable diagnostics.
We recommend that this analysis be extended to non-
epidemic settings with more complex treatment options
and host susceptibility patterns, and that better data be
gathered to inform parameter input, especially as regards
the clinical and economic consequences of misdiagnosis.
While such evidence is missing, we believe based on our
ﬁndings that decision makers adopting a ‘do no harm’
principle should, despite a (relatively small) added cost,
strongly consider RDT use throughout or during part of a
malaria epidemic, where this is feasible given local human
resources and logistics conditions.
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Table 3 Calculation of net beneﬁts of RDTs over presumptive strategy (¼ excess deaths averted and hospital costs saved) among children
under 5, based on 10 000 fever cases, a malaria prevalence of 50% and a proportion of potentially fatal ARI cases of 50% among all non-
malaria fever cases. ‘Health access’ means proportion of (severe or non-severe) cases obtaining care. Sensitivity and speciﬁcity of strategies
are as in Table 1. Other parameters implied in calculations are: (i) per cent of untreated malaria cases becoming severe ¼ 5% (Goodman
et al. 1999), (ii) severe malaria CFR if treated ¼ 19.2% (Goodman et al. 2000), (iii) severe malaria CFR if untreated ¼ 50% (Goodman
et al. 2000), (iv) percent of untreated ARI cases becoming severe ¼ 9.2% (Rudan et al. 2004), (v) percent of treated ARI cases becoming
severe ¼ 4.6% [based on 50% reduction in mortality risk if treated promptly; (Enarson et al. 2005)], (vi) severe ARI CFR if treated ¼
9.9% (Rudan et al. 2004), (vii) severe ARI CFR if untreated ¼ 40% [based on pre-antibiotic era; (Graham 2002)], (viii) cost to health
system of one hospital stay ¼ € 52.3 [based on typical stay of 4.5 days; (Goodman et al. 2000)]
Health access ¼ 25% Health access ¼ 75%
Presumptive
strategy
RDT-based
strategy
Presumptive
strategy
RDT-based
strategy
Harm: excess malaria deaths and malaria hospitalisation costs due to false negatives missed by RDTs
Malaria cases missed and left untreated (false negatives) 0 250 0 250
Untreated malaria cases becoming severe 0 13 0 13
Severe cases receiving inpatient treatment 0 3 0 9
Treated or untreated severe cases dying (dm)0 5 0 3
Total cost of inpatient malaria treatment (€)( Cm) 0 163 0 490
Beneﬁt: less ARI deaths and ARI hospitalisation costs due to false positives averted by RDTs
Non-malaria fever cases detected (false positives averted) (a) 0 4700 0 4700
ARI cases 2500 2500 2500 2500
ARI cases wrongfully treated as malaria 2500 150 2500 150
ARI cases not wrongfully treated and receiving further
outpatient treatment for ARI
0 588 0 1763
ARI cases (treated or untreated) becoming severe 230 203 230 149
Severe ARI cases receiving inpatient treatment 58 51 173 112
Treated or untreated severe ARI cases dying 75 66 40 26
Total deaths averted (da)9 1 4
Total cost of inpatient ARI treatment (€) 3005 2652 9014 5837
Total cost saving (€)( Ca) – 353 – 3177
Net beneﬁt:
Total deaths averted through RDT strategy (¼da)dm)–4 – 1 1
Total hospital cost saving (€)( S ¼ Ca)Cm) – 190 – 2688
Hospital cost saving per false positive averted (€)( ¼ S/a) – 0.04 – 0.6
We assume that non-malaria ARI cases that are wrongfully treated with ACT will not visit a second source of outpatient care. They may
however, seek inpatient care if they aggravate.
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ª 2006 Blackwell Publishing Ltd 407Re ´ponse ope ´rationnelle aux e ´pide ´mies de malaria: les tests de diagnostic rapides ont-ils un bon rapport cou ˆts-efﬁcacite ´?
objectif Comparer le rapport cou ˆts-efﬁcacite ´ du traitement de la malaria base ´ sur le diagnostic pre ´somptif a ` celui du traitement base ´ sur l’utilisation
des tests de diagnostic rapides (TDRs).
me ´thodes Nous avons calcule ´ les cou ˆts directs (base ´s sur l’expe ´rience de l’Ethiopie et du sud du Soudan) et l’efﬁcacite ´ (en terme de re ´duction du
surtraitement) d’un programme de traitement gratuit et de ´centralise ´ utilisant l’arte ´sumate plus l’amodiaquine (AS+AD) ou l’artemether-lumefantrine
(ART-LUM) dans une e ´pide ´mie a ` Plasmodium falciparum. Notre principale mesure du rapport cou ˆts-efﬁcacite ´ e ´tait le cou ˆt incre ´mental par traitement
d’un faux positif identiﬁe ´ par les TDRs.
re ´sultats Alors que la pre ´valence de la malaria augmente, la diffe ´rence dans les cou ˆts entre les traitements base ´s sur la pre ´somption et les TDRs
augmentent e ´galement. Le seuil de pre ´valence au-dela ` duquel les strate ´gies base ´es sur les TDRs deviennent plus cou ˆteuses est de 21% dans le sce ´nario
AS+AQ et 55% dans celui du ART-LUM. Mais, ces seuils augmentent a ` 58% et 70% respectivement lorsque le corps ﬁnancier tole `re un cou ˆt
incre ´mental de 1€ par faux positifs e ´vite ´s. Toutefois, me ˆme dans une pre ´valence e ´leve ´e (90%) de malaria dans le cas d’un pique d’e ´pide ´mie, une strate ´gie
base ´e sur les TDRs cou ˆterait mode ´re ´ment plus que la strate ´gie pre ´somptive: +29,9% dans le sce ´nario AS+AQ et +19,4% dans celui de l’ART-LUM. La
comparaison des traitements est peu inﬂuence ´e par la distribution de l’a ˆge et des grossesses dans les cas de ﬁe `vres. Mais, elle est fortement affecte ´e par les
variations dans les cou ˆts non biologiques. Si les prix a ` l’unite ´ des TDRs e ´taient re ´duits de moitie ´ ils auraient un bon rapport cou ˆts-efﬁcacite ´ dans une
pre ´valence de malaria allant jusqu’a ` 45% dans le cas du traitement a l’AS+AQ et jusqu’a ` 68% dans le traitement a l’ART-LUM.
conclusion Dans la plupart des sce ´narios de pre ´valence d’e ´pide ´mie, les TDRs re ´duiraient conside ´rablement le surtraitement avec seulement une
augmentation mode ´re ´e des cou ˆts par rapport au diagnostic pre ´somptif. Une diminution substantielle du prix unitaire des TDRs augmenterait e ´nor-
me ´ment leur rapport cou ˆts-efﬁcacite ´ et ils devraient alors e ˆtre recommande ´s. La tole ´rance d’un cou ˆt incre ´mental de 1 € est probablement justiﬁe ´ea uv u
de la sante ´ publique en ge ´ne ´rale et des be ´ne ´ﬁces ﬁnanciers. Les TDRs devraient e ˆtre conside ´re ´es pour les e ´pide ´mies de malaria si les ressources logistiques
et humaines le permettent.
mots cle ´s Plasmodium falciparum, malaria, e ´pide ´mique, test de diagnostic rapide, traitement pre ´somptif, cou ˆts-efﬁcacite ´
Respuesta operativa a epidemias de malaria: ¿‘son costo-efectivos los test de diagno ´stico ra ´pido?
objetivo Comparar la costo-efectividad del tratamiento de malaria, basado en un diagno ´stico presuntivo, con el tratamiento de malaria basado en un
test diagno ´stico ra ´pido (TDRs).
me ´todos Calculamos los costes directos (basados en experiencias en Etiopı ´a y el sur de Suda ´n) y la efectividad (en te ´rminos de reducir el sobre-
tratamiento) de un programa de tratamiento gratis y descentralizado, utilizando artesunato ma ´s amodiaquina (AS+AQ) o artemeter-lumefantrina (ART-
LUM) en una epidemia de Plasmodium falciparum. Nuestra principal medida de costo-efectividad fue el coste incremental por cada tratamiento de un
falso positivo prevenido por TDRs.
resultados A medida que aumenta la prevalencia de malaria, la diferencia entre el costo del tratamiento presuntivo y aquel basado en TDRs aumenta.
La prevalencia umbral, por encima de la cual la estrategia basada en diagno ´stico por TDRs se convierte en ma ´s cara, es del 21% en el caso de AS+AQ y
del 55% para ART-LUM. Estos umbrales aumentan a 58% y 70% respectivamente si el ﬁnanciador tolera un coste incremental de 1 € por falso positivo
prevenido. Sin embargo, au ´n con una alta prevalencia (90%) de malaria, consistente con un pico epide ´mico, una estrategia basada en TDRs solo costarı ´a
moderadamente ma ´s que la estrategia de tratamiento presuntivo: +29.9% en el escenario de AS+AQ y +19.4% para ART-LUM. La comparacio ´nd e l
tratamiento es insensible a la distribucio ´n de edad y embarazos de los casos febriles, pero esta ´ muy afectada por la variacio ´n de costes no-biome ´dicos. Si
el precio de la unidad fuese la mitad, los TDRs serı ´an ma ´s costo efectivos con una prevalencia de malaria de hasta un 45% en el caso del tratamiento con
AS+AQ y con una prevalencia de hasta un 68% para el tratamiento con ART-LUM.
conclusio ´n En la mayorı ´a de los escenarios epide ´micos, los TDRs reducirı ´an considerablemente el sobre-tratamiento con solo un incremento
moderado de los costes sobre el diagno ´stico presuntivo. Una disminucio ´n sustancial en el precio de los TDRs aumentarı ´a enormemente su costo-
efectividad, y se deberı ´a por lo recomendar. Un coste incremental tolerado de 1 € esta ´ probablemente justiﬁcado, dados los beneﬁcios ﬁnancieros y de
salud pu ´blica en general. Los TDRs deberı ´an considerarse en epidemias de malaria, si los recursos logı ´sticos y humanos lo permiten.
palabras clave Plasmodium falciparum, malaria, epidemia, test diagno ´stico ra ´pido, tratamiento presuntivo, costo efectividad
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